Teneligliptin

Teneligliptin is a topic that has captured the attention of many people over the years. With a history rich in significant events and facts, Teneligliptin has left an indelible mark on society and has generated countless reflections and debates. From its origins to its relevance today, Teneligliptin has been the subject of study, analysis and admiration by experts and fans alike. In this article, we will explore in detail the various aspects of Teneligliptin, its impacts in different areas and its influence on people's daily lives.

Teneligliptin
Clinical data
Trade namesTenelia
ATC code
Legal status
Legal status
  • Approved in Japan
Identifiers
  • {(2S,4S)-4--2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H30N6OS
Molar mass426.58 g·mol−1
3D model (JSmol)
  • CC1=NN(C(=C1)N2CCN(CC2)3C(NC3)C(=O)N4CCSC4)C5=CC=CC=C5
  • InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
  • Key:WGRQANOPCQRCME-PMACEKPBSA-N

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[1]

Creation

It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.[2]

Licensing and use

Japan/Korea/India/Argentina

It is approved for use in Japan, Argentina, Korea and India.[3]

Pharmacology

Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.

Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.[4]

References

  1. ^ Kishimoto M (2013). "Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes". Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 6: 187–195. doi:10.2147/DMSO.S35682. PMC 3650886. PMID 23671395.
  2. ^ "TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy". Media & Investors. Daiichi Sankyo. 20 December 2013. Archived from the original on 24 November 2015.
  3. ^ Bronson J, Black A, Dhar TG, Ellsworth BA, Merritt JR (2013). "Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012". Annual Reports in Medicinal Chemistry. Vol. 48. pp. 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 978-0-12-417150-3.
  4. ^ Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T (May 2013). "A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site". Biochemical and Biophysical Research Communications. 434 (2): 191–196. doi:10.1016/j.bbrc.2013.03.010. PMID 23501107.